Halozyme Therapeutics, Inc. · NASDAQ:HALO

Torley Helen sold 60,000 Halozyme Therapeutics, Inc. shares (Form 4)

Traded Sep 9 to Sep 11, 2026 · Filed Sep 11, 2026

From Sep 9 to Sep 11, 2026, Torley Helen (Director, PRESIDENT AND CEO) sold 60,000 Halozyme Therapeutics, Inc. shares at an average US$107.28 for US$6.44M under a trading plan, leaving 767,780 shares. Filed Sep 11, 2026 (Form 4).

Sold
60,000 shares
Price
US$107.28 average (US$107.01 to US$108.67)
Value
US$6.44M
Holding after
767,780 shares
Trading plan
Yes (Made under a plan set in advance)
Role
Director, PRESIDENT AND CEO

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
Sep 9, 2026Common StockOption exercise20,000US$18.41787,780Direct
Sep 9, 2026Common StockSale13,304US$107.22774,476Direct
Sep 9, 2026Common StockSale6,596US$107.82767,880Direct
Sep 9, 2026Common StockSale100US$108.67767,780Direct
Sep 10, 2026Common StockOption exercise20,000US$18.41787,780Direct
Sep 10, 2026Common StockSale14,588US$107.01773,192Direct
Sep 10, 2026Common StockSale5,412US$107.58767,780Direct
Sep 11, 2026Common StockOption exercise20,000US$18.41787,780Direct
Sep 11, 2026Common StockSale15,492US$107.15772,288Direct
Sep 11, 2026Common StockSale4,508US$107.55767,780Direct

Source

View original at SEC

Related